Senseonics Holdings IncFRA Senseonics Stock Report

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually to measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Freedom product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor, which can be utilized with a smart transmitter to get continuous glucose readings and alerts, or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose reading without a smart transmitter.